Neurochemical Research

, Volume 37, Issue 1, pp 143–152 | Cite as

BDNF-, IGF-1- and GDNF-Secreting Human Neural Progenitor Cells Rescue Amyloid β-Induced Toxicity in Cultured Rat Septal Neurons

  • Narisorn Kitiyanant
  • Yindee Kitiyanant
  • Clive N. Svendsen
  • Wipawan Thangnipon
Original Paper


Alzheimer’s disease (AD) is characterized by the depositions of amyloid-β (Aβ) proteins, resulting in a reduction of choline acetyltransferase (ChAT) activity of AD brain in the early stages of the disease. Several growth factors, including brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF)-1 and glial cell-derived neurotrophic factor (GDNF) are known to protect neuronal cell death in several neurodegenerative both in vitro and in vivo models. In this study, septal neurons were prepared from septal nucleus of embryonic (day 16-17) rat brain and treated with monomeric, oligomeric or fibrillar Aβ1-42 peptide. Oligomeric Aβ1-42, (10 μM) was the most potent at sublethal dose. Septal neuron cultures treated with BDNF, IGF-1 or GDNF or co-cultured with genetically modified human neural progenitor cells (hNPCs) secreting these neurotrophic factors (but not allowing contact between the two cell types), were protected from oligomeric Aβ1-42 peptide-induced cell death, and these trophic factors enhanced cholinergic functions by increasing ChAT expression level. These results indicate the potential of employing transplanted hNPCs for treatment of AD.


Amyloid-β Neurotrophic factors Neural progenitor cells Septal neurons Choline acetyltransferase 



We thank the Office of the Higher Education Commission, Thailand, for providing grant funds via the Strategic Scholarships for Frontier Research Network for the Joint Ph.D. Program Thai Doctoral Degree for NK. This work was partially supported by Mahidol University, grant no. 02011868-0004. We are thankful to Masatoshi Suzuki and Craig Atwood at the University of Wisconsin-Madison, USA for their advice on experimental techniques and Prof. Prapon Wilairat for his critical reading in the manuscript.


  1. 1.
    Francis PT, Palmer AM, Snape M et al (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147PubMedCrossRefGoogle Scholar
  2. 2.
    Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403PubMedCrossRefGoogle Scholar
  3. 3.
    Schliebs R (2005) Basal forebrain cholinergic dysfunction in Alzheimer’s disease–interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 30:895–908PubMedCrossRefGoogle Scholar
  4. 4.
    LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8:499–509PubMedCrossRefGoogle Scholar
  5. 5.
    Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet 19:R12–R20PubMedCrossRefGoogle Scholar
  6. 6.
    Castro A, Martinez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12:4377–4387PubMedCrossRefGoogle Scholar
  7. 7.
    Holzgrabe U, Kapkova P, Alptuzun V et al (2007) Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 11:161–179PubMedCrossRefGoogle Scholar
  8. 8.
    Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381–391PubMedCrossRefGoogle Scholar
  9. 9.
    Tuszynski MH (2002) Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 1:51–57PubMedCrossRefGoogle Scholar
  10. 10.
    Blurton-Jones M, Kitazawa M, Martinez-Coria H et al (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 106:13594–13599PubMedCrossRefGoogle Scholar
  11. 11.
    Suzuki M, Svendsen CN (2008) Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 31:192–198PubMedCrossRefGoogle Scholar
  12. 12.
    Tuszynski MH, Thal L, Pay M et al (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551–555PubMedCrossRefGoogle Scholar
  13. 13.
    Nagahara AH, Merrill DA, Coppola G et al (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 15:331–337PubMedCrossRefGoogle Scholar
  14. 14.
    Chourbaji S, Hellweg R, Brandis D et al (2004) Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Brain Res Mol Brain Res 121:28–36PubMedCrossRefGoogle Scholar
  15. 15.
    Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer’s disease. Eur J Pharmacol 490:127–133PubMedCrossRefGoogle Scholar
  16. 16.
    de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 7:45–61Google Scholar
  17. 17.
    Golden JP, Milbrandt J, Johnson EM Jr (2003) Neurturin and persephin promote the survival of embryonic basal forebrain cholinergic neurons in vitro. Exp Neurol 184:447–455PubMedCrossRefGoogle Scholar
  18. 18.
    Straten G, Eschweiler GW, Maetzler W et al (2009) Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer’s disease and normal controls. J Alzheimers Dis 18:331–337PubMedGoogle Scholar
  19. 19.
    Ebert AD, Svendsen CN (2005) A new tool in the battle against Alzheimer’s disease and aging: ex vivo gene therapy. Rejuvenation Res 8:131–134PubMedCrossRefGoogle Scholar
  20. 20.
    Ebert AD, Barber AE, Heins BM et al (2010) Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington’s disease. Exp Neurol 224:155–162PubMedCrossRefGoogle Scholar
  21. 21.
    Ebert AD, Beres AJ, Barber AE et al (2008) Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson’s disease. Exp Neurol 209:213–223PubMedCrossRefGoogle Scholar
  22. 22.
    Suzuki M, McHugh J, Tork C et al (2007) GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2:e689PubMedCrossRefGoogle Scholar
  23. 23.
    Schnitzler AC, Lopez-Coviella I, Blusztajn JK (2008) Purification and culture of nerve growth factor receptor (p75)-expressing basal forebrain cholinergic neurons. Nat Protoc 3:34–40PubMedCrossRefGoogle Scholar
  24. 24.
    Svendsen CN, ter Borg MG, Armstrong RJ et al (1998) A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 85:141–152PubMedCrossRefGoogle Scholar
  25. 25.
    Capowski EE, Schneider BL, Ebert AD et al (2007) Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods 163:338–349PubMedCrossRefGoogle Scholar
  26. 26.
    Dahlgren KN, Manelli AM, Stine WB Jr et al (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277:32046–32053PubMedCrossRefGoogle Scholar
  27. 27.
    Soiampornkul R, Tong L, Thangnipon W et al (2008) Interleukin-1beta interferes with signal transduction induced by neurotrophin-3 in cortical neurons. Brain Res 1188:189–197PubMedCrossRefGoogle Scholar
  28. 28.
    Fuentealba RA, Farias G, Scheu J et al (2004) Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev 47:275–289PubMedCrossRefGoogle Scholar
  29. 29.
    Smith WW, Gorospe M, Kusiak JW (2006) Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer’s disease. CNS Neurol Disord Drug Targets 5:355–361PubMedCrossRefGoogle Scholar
  30. 30.
    Gandy S (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 115:1121–1129PubMedGoogle Scholar
  31. 31.
    Giuffrida ML, Caraci F, Pignataro B et al (2009) Beta-amyloid monomers are neuroprotective. J Neurosci 29:10582–10587PubMedCrossRefGoogle Scholar
  32. 32.
    Esposito E, Cuzzocrea S (2010) New therapeutic strategy for Parkinson’s and Alzheimer’s disease. Curr Med Chem 17:2764–2774PubMedCrossRefGoogle Scholar
  33. 33.
    Song MS, Saavedra L, de Chaves EI (2006) Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Abeta in distal axons. Neurobiol Aging 27:1224–1238PubMedCrossRefGoogle Scholar
  34. 34.
    Suzuki M, McHugh J, Tork C et al (2008) Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 16:2002–2010PubMedCrossRefGoogle Scholar
  35. 35.
    Sarabi A, Hoffer BJ, Olson L et al (2003) Glial cell line neurotrophic factor-family receptor alpha-1 is present in central neurons with distinct phenotypes. Neuroscience 116:261–273PubMedCrossRefGoogle Scholar
  36. 36.
    Bondy C, Werner H, Roberts CT Jr et al (1992) Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience 46:909–923PubMedCrossRefGoogle Scholar
  37. 37.
    Burgess A, Aubert I (2006) Polysialic acid limits choline acetyltransferase activity induced by brain-derived neurotrophic factor. J Neurochem 99:797–806PubMedCrossRefGoogle Scholar
  38. 38.
    Gomez JM (2008) Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer’s disease. Endocr Metab Immune Disord Drug Targets 8:143–151PubMedCrossRefGoogle Scholar
  39. 39.
    Jarvis K, Assis-Nascimento P, Mudd LM et al (2007) Beta-amyloid toxicity and reversal in embryonic rat septal neurons. Neurosci Lett 423:184–188PubMedCrossRefGoogle Scholar
  40. 40.
    Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383–394PubMedCrossRefGoogle Scholar
  41. 41.
    Baloh RH, Enomoto H, Johnson EM Jr et al (2000) The GDNF family ligands and receptors—implications for neural development. Curr Opin Neurobiol 10:103–110PubMedCrossRefGoogle Scholar
  42. 42.
    Araujo DM, Hilt DC, Miller PJ et al (1997) ret receptor tyrosine kinase immunoreactivity is altered in glial cell line-derived neurotrophic factor-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways. Neuroscience 80:9–16PubMedCrossRefGoogle Scholar
  43. 43.
    Golden JP, Baloh RH, Kotzbauer PT et al (1998) Expression of neurturin, GDNF, and their receptors in the adult mouse CNS. J Comp Neurol 398:139–150PubMedCrossRefGoogle Scholar
  44. 44.
    Golden JP, DeMaro JA, Osborne PA et al (1999) Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp Neurol 158:504–528PubMedCrossRefGoogle Scholar
  45. 45.
    Ha DH, Robertson RT, Ribak CE et al (1996) Cultured basal forebrain cholinergic neurons in contact with cortical cells display synapses, enhanced morphological features, and decreased dependence on nerve growth factor. J Comp Neurol 373:451–465PubMedCrossRefGoogle Scholar
  46. 46.
    Williams LR, Inouye G, Cummins V et al (1996) Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J Pharmacol Exp Ther 277:1140–1151PubMedGoogle Scholar
  47. 47.
    Gerlai R, McNamara A, Choi-Lundberg DL et al (2001) Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur J Neurosci 14:1153–1163PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Narisorn Kitiyanant
    • 1
    • 2
  • Yindee Kitiyanant
    • 2
    • 3
  • Clive N. Svendsen
    • 4
  • Wipawan Thangnipon
    • 1
  1. 1.Research Center for Neuroscience, Institute of Molecular BiosciencesMahidol UniversityNakhon PathomThailand
  2. 2.Reproductive and Stem Cell Biology Research Group, Institute of Molecular BiosciencesMahidol UniversityNakhon PathomThailand
  3. 3.Department of Anatomy, Faculty of ScienceMahidol UniversityBangkokThailand
  4. 4.Regenerative Medicine InstituteCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations